High Efficacy and Safety of Asciminib in a Chronic Myeloid Leukemia Patient with Chronic Kidney Disease Following Renal Transplantation: A Case Report

Yasuhiro Uchida; Daisuke Koyama; Kazuya Manabe; Kengo Suzuki; Naomi Asano; Mamiko Endo; Masahiko Fukatsu; Takahiro Sano; Kiyohito Hayashi; Motoki Takano; Hiroshi Takahashi; Satoshi Kimura; Takayuki Ikezoe

doi:10.2169/internalmedicine.2179-23

This article has now been updated. Please use the final version.

High Efficacy and Safety of Asciminib in a Chronic Myeloid Leukemia Patient with Chronic Kidney Disease Following Renal Transplantation: A Case Report

Yasuhiro Uchida, Daisuke Koyama, Kazuya Manabe, Kengo Suzuki, Naomi Asano, Mamiko Endo, Masahiko Fukatsu, Takahiro Sano, Kiyohito Hayashi, Motoki Takano, Hiroshi Takahashi, Satoshi Kimura, Takayuki Ikezoe

Author information

Keywords: chronic myeloid leukemia, chronic kidney disease, renal transplantation, BCR::ABL1, asciminib, tyrosine kinase inhibitor

JOURNAL OPEN ACCESS Advance online publication

Article ID: 2179-23

DOI https://doi.org/10.2169/internalmedicine.2179-23

The final version of this article is now available: Vol. 63 (2024), No. 5 pp. 717-720

Details

Abstract

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm driven by the BCR::ABL1 tyrosine kinase. Tyrosine kinase inhibitors (TKIs) have been established as standard therapies for CML. However, some CML patients experience TKI intolerance. Asciminib was approved for CML patients either intolerant or refractory to TKI therapy. We herein report a 63-year-old CML patient who underwent renal transplantation and exhibited TKI intolerance. He was switched to asciminib, which achieved a deep molecular response without exacerbation of the renal function. Our experience revealed that asciminib is effective and safe for CML patients complicated with chronic kidney disease.

Corresponding author

Register with J-STAGE for free!